Volume 5.45 | Dec 2

Pancreatic Cell News 5.45 December 2, 2014
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PACN on Twitter
 
TOP STORY
Targeted Oncolytic HSV-1 Eradicate Experimental Pancreatic Tumors
Researchers used Myb34.5, a second-generation replication-conditional HSV-1 mutant in which ICP6 gene expression is defective and expression of the HSV-1 γ34.5 gene is regulated by the cellular B-myb promoter. Myb34.5 replicates to high level in human pancreatic ductal adenocarcinoma cell lines and is associated with cell death by apoptosis. [Hum Gene Ther] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
DIABETES & PANCREATITIS

Transcriptional Profiling Reveals Functional Links between RasGrf1 and Pttg1 in Pancreatic Beta Cells
Researchers compared the transcriptional profile of highly purified pancreatic islets from RasGrf1 KO mice to that of WT control animals using commercial oligonucleotide microarrays. RasGrf1 elimination resulted in differential gene expression of numerous components of MAPK- and calcium-signaling pathways, suggesting a relevant contribution of this guanine nucleotide exchange factor to modulation of cellular signaling in the cell lineages integrating the pancreatic islets. [BMC Genomics] Full Article

Di(2-Ethylhexyl) Phthalate-Induced Apoptosis in Rat INS-1 Cells Is Dependent on Activation of Endoplasmic Reticulum Stress and Suppression of Antioxidant Protection
Scientists investigated the cytotoxic effects of di(2-ethylhexyl) phthalate (DEHP) on INS-1 cells and to explore the related underlying mechanisms. They showed that DEHP decreased insulin secretion and content and induced apoptosis in INS-1 cells in a dose-dependent manner. [J Cell Mol Med] Full Article

Omega-3 Supplementation Improves Pancreatic Islet Redox Status: In Vivo and In Vitro Studies
Researchers evaluated the potential changes induced by fish oil supplementation on the redox status of pancreatic islets from healthy rats. To test whether these effects were due to eicosapentaenoic acid and docosahexaenoic acid (omega-3), in vitro experiments were performed. [Pancreas] Abstract

The ACE2-Angiotensin-(1-7)-Mas Axis Protects against Pancreatic Cell Damage in Cell Culture
Angiotensin-converting enzyme 2 (ACE2), its product angiotensin-(1-7), and its receptor Mas have been shown to moderate the adverse effects of the ACE-angiotensin II-AT1 axis in many diseases. Scientists determined whether the ACE2-Ang-(1-7)-Mas axis could have similar effects in a cell culture model of pancreatic damage. [Pancreas] Abstract

Overexpression of Angiotensin II Type 2 Receptor Promotes Apoptosis and Impairs Insulin Secretion in Rat Insulinoma Cells
Scientists evaluated the effects of overexpressing activation of Ang II type 2 receptor (AT2R) by viral vector transduction on the apoptosis and function of pancreatic β-islet cells. The rat insulinoma cell line, INS-1, was transduced with a recombinant adenoviral vector expressing AT2R. [Mol Cell Biochem] Abstract

PANCREATIC CANCER

Neurogenin 3-Directed Cre Deletion of Tsc1 Gene Causes Pancreatic Acinar Carcinoma
Scientists show that neurogenin 3 directed Cre deletion of Tsc1 gene induces the development of pancreatic acinar carcinoma. [Neoplasia] Full Article

Nuclear Localized FAM21 Participates in NF-κB-Dependent Gene Regulation in Pancreatic Cancer Cells
Investigators demonstrate that FAM21 depletion sensitizes pancreatic cancer cells to gemcitabine and 5-fluorouracil. [J Cell Sci] Abstract

miR-23a/-24-Induced Gene Silencing Results in Mesothelial Cell Integration of Pancreatic Cancer
Researchers examined the invasion of pancreatic ductal adenocarcinoma (PDAC) cells into the mesothelial barrier and identified the related microRNA (miRNA) expression profiles. The interactions between PDAC cells and mesothelial monolayers were characterized and quantified using a specific time-lapse videomicroscopy assay. [Br J Cancer] Abstract

The Marine Natural Product Microsclerodermin A Is a Novel Inhibitor of the Nuclear Factor Kappa B and Induces Apoptosis in Pancreatic Cancer Cells
Microsclerodermin A is shown here to inhibit nuclear factor kappa B (NFκB) transcriptional activity in a reporter cell line, to reduce levels of phosphorylated NFκB in the AsPC-1 cell line, to have an IC50 for cytotoxicity in the low micromolar range against the AsPC-1, BxPC-3, MIA PaCa-2 and PANC-1 pancreatic cancer cell lines, and to induce significant apoptosis in the AsPC-1, BxPC-3 and the PANC-1 cell lines. [Invest New Drugs] Abstract

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now.
 
REVIEWS
Regulatory Role of Adenosine in Insulin Secretion from Pancreatic β-Cells-Action via Adenosine A1 Receptor and Beyond
Under physiological conditions, insulin secretion from pancreatic β-cells is tightly regulated by different factors, including nutrients, nervous system, and other hormones. Pancreatic β-cells are also influenced by paracrine and autocrine interactions. [J Physiol Biochem] Abstract

Epithelial-Mesenchymal Transition in Pancreatic Cancer: Is it a Clinically Significant Factor?
Emerging data suggest that inhibiting epithelial-mesenchymal transition (EMT) may reverse the EMT phenotype and enhance the efficacy of chemotherapeutic agents against pancreatic cancer cells. [Biochim Biophys Acta] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
 
INDUSTRY NEWS
Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Merck announced that the company has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency. [Merck & Co., Inc.] Press Release

PharmaEngine Announces the Receipt of US FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer by Merrimack
PharmaEngine, Inc. and its partner Merrimack Pharmaceuticals, Inc. announced that MM-398 has been granted the Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. [PharmaEngine, Inc.] Press Release

Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers
Oncolytics Biotech Inc. announced that it has submitted applications for orphan drug designation to the U.S. Food and Drug Administration (FDA) for REOLYSIN® for the treatment of pancreatic and ovarian cancers. [Oncolytics Biotech Inc.] Press Release

Momenta Pharmaceuticals’ Necuparanib Receives Fast Track Designation from the FDA for the Treatment of Patients with Metastatic Pancreatic Cancer
Momenta Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigation of necuparanib, the company’s novel oncology drug candidate, as a first-line treatment in combination with Abraxane® and gemcitabine in patients with metastatic pancreatic cancer. [Momenta Pharmaceuticals, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 4th Annual Cell Line Engineering & Development Asia
May 19-22, 2015
Shanghai, China

Visit our events page to see a complete list of events in the pancreatic cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellowship – Diabetes Research/Cellular Metabolism (Lund University)

Research Assistants – Diabetes & Metabolism (Garvan Institute of Medical Research)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Position – Cancer Drug Delivery (University of Tartu)

PhD Studentship – Driving Cells Towards a Pancreatic Fate (University of Edinburgh)

Postdoctoral Position – Endothelial Dysfunction and Diabetes (Weill Cornell Medical College in Qatar)

Associate or Full Professor – Pediatric Diabetes and Metabolic Disease (University of California San Diego)

Postdoctoral Fellowship Position – Obesity and Diabetes Pathogenesis (NIDDK / NIH)

Research Assistant – Diabetes/Metabolic Health (The Nestlé Institute of Health Sciences)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us